Kilitch Drugs (India) Ltd
KILITCH NSE
Kilitch Drugs (India) Ltd
HealthcareNSE: KILITCH BSE: 524500 Pharmaceuticals
Key Fundamentals
MicrocapPharmaceuticalsHealthcareMarket Cap
₹580 Cr
Volatility
Moderate
P/E Ratio
19.91
EBITDA
₹47.80 Cr
Return on Equity
10.66%
Debt to Equity
0.32
Book Value
₹79.99
52W High
₹439
52W Low
₹117.25
Insights
BetaAI-extracted from concalls & annual reports · figures as reported, with sources
Log in to view Kilitch Drugs (India) Ltd insights
32 extracted metrics + investor summaries across FY15–FY26.
Tapetide Score
Data-driven rating, 0–100. How it works →
Technical Indicators
Key Insights
Strengths
2- Company has delivered good profit growth of 54.7% CAGR over last 5 years
- Company's median sales growth is 28.4% of last 10 years
Weaknesses
4- Though the company is reporting repeated profits, it is not paying out dividend
- Company has a low return on equity of 10.2% over last 3 years.
- Company has high debtors of 186 days.
- Promoter holding has decreased over last 3 years: -4.47%
Growth Rate
Revenue Growth
17.76% ↗
Net Income Growth
18.47% ↗
Cash Flow Change
36.60% ↗
ROE
-14.31% ↗
ROCE
-23.99% ↗
EBITDA Margin (Avg.)
-4.72% ↗
Quarterly Results
| Jun 2023 | Sep 2023 | Dec 2023 | Mar 2024 | Jun 2024 | Sep 2024 | Dec 2024 | Mar 2025 | Jun 2025 | Sep 2025 | Dec 2025 | Mar 2026 | Jun 2026 | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Sales | 36.56 | 41.2 | 31.79 | 44.82 | 33.45 | 47.47 | 56.17 | 61.23 | 43.14 | 48.92 | 53.81 | 89.6 | 44.88 |
| Expenses | 30.38 | 32.58 | 29.51 | 37.74 | 31.79 | 41.37 | 47.44 | 46.64 | 39.88 | 43.88 | 47.66 | 67.46 | 41.94 |
| Operating Profit | 6.18 | 8.62 | 2.28 | 7.08 | 1.66 | 6.1 | 8.73 | 14.59 | 3.26 | 5.04 | 6.15 | 22.14 | 2.94 |
| OPM % | 16.9% | 20.92% | 7.17% | 15.8% | 4.96% | 12.85% | 15.54% | 23.83% | 7.56% | 10.3% | 11.43% | 24.71% | 6.55% |
| Other Income | 0.56 | 0.49 | 2.96 | 0.47 | 2.57 | 5.16 | 1.73 | 1.7 | 2.56 | 6.66 | 1.53 | 0.49 | 2.9 |
| Interest | 1.5 | 1.51 | 1.6 | 1.32 | 1.73 | 0.31 | 1.4 | 1.6 | 1.53 | 1.44 | 1.15 | 1.44 | 0.88 |
| Depreciation | 0.71 | 0.82 | 0.81 | 0.93 | 0.85 | 0.61 | 0.81 | 0.85 | 0.84 | 0.86 | 0.94 | 0.98 | 1.09 |
| PBT | 4.53 | 6.78 | 2.83 | 5.3 | 1.65 | 10.34 | 8.25 | 13.84 | 3.45 | 9.4 | 5.59 | 20.21 | 3.87 |
| Tax % | 32.67% | 24.93% | 38.16% | 30.57% | 93.33% | 16.73% | 32% | 26.23% | 34.49% | 14.47% | 22.9% | 26.37% | 48.84% |
| Net Profit | 3.06 | 5.09 | 1.74 | 3.68 | 0.11 | 8.61 | 5.61 | 10.22 | 2.27 | 8.04 | 4.31 | 14.88 | 1.96 |
| EPS in Rs | 0.99 | 1.35 | 0.83 | 1.03 | 0.38 | 2.46 | 1.7 | 2.97 | 0.87 | 2.34 | 1.27 | 4.15 | 0.83 |
Profit & Loss
| Mar 2015 | Mar 2016 | Mar 2017 | Mar 2018 | Mar 2019 | Mar 2020 | Mar 2021 | Mar 2022 | Mar 2023 | Mar 2024 | Mar 2025 | Mar 2026 | TTM | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Sales | 19 | 21 | 27 | 51 | 82 | 53 | 68 | 114 | 140 | 154 | 198 | 235 | 237 |
| Expenses | 21 | 25 | 28 | 45 | 75 | 53 | 63 | 104 | 122 | 130 | 167 | 198 | 201 |
| Operating Profit | -2 | -4 | -1 | 6 | 7 | 0 | 5 | 10 | 18 | 24 | 32 | 37 | 36 |
| OPM % | -9% | -19% | -2% | 11% | 9% | 0.8% | 8% | 9% | 13% | 16% | 16% | 16% | 15% |
| Other Income | 3 | 2 | 1 | 3 | 4 | 4 | 3 | 3 | 3 | 4 | 11 | 11 | 12 |
| Interest | 0 | 0 | 0 | 0 | 1 | 1 | 1 | 1 | 5 | 6 | 5 | 6 | 5 |
| Depreciation | 2 | 10 | 10 | 2 | 2 | 2 | 2 | 2 | 4 | 3 | 3 | 4 | 4 |
| PBT | -1 | -12 | -9 | 6 | 9 | 2 | 5 | 10 | 12 | 19 | 34 | 39 | 39 |
| Tax % | -70% | -4% | -5% | 16% | 55% | 48% | 27% | 35% | 31% | 30% | 28% | 24% | — |
| Net Profit | 0 | -11 | -9 | 5 | 4 | 1 | 4 | 6 | 8 | 14 | 25 | 30 | 29 |
| EPS in Rs | -0.1 | -3.89 | -3.09 | 1.72 | 1.15 | 0.25 | 1.09 | 2.17 | 3.08 | 4.17 | 7.63 | 8.63 | 8.59 |
| Div. Payout % | 0% | 0% | 0% | 13% | 20% | 0% | 0% | 0% | 0% | 0% | 0% | 0% | — |
Balance Sheet
| Mar 2015 | Mar 2016 | Mar 2017 | Mar 2018 | Mar 2019 | Mar 2020 | Mar 2021 | Mar 2022 | Mar 2023 | Mar 2024 | Mar 2025 | Mar 2026 | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Equity Capital | 13 | 13 | 13 | 14 | 15 | 15 | 15 | 16 | 16 | 16 | 16 | 35 |
| Reserves | 107 | 95 | 88 | 98 | 106 | 103 | 112 | 124 | 136 | 160 | 186 | 245 |
| Borrowings | 0 | 0 | 1 | 1 | 9 | 13 | 15 | 20 | 22 | 32 | 49 | 89 |
| Other Liabilities | 7 | 8 | 11 | 15 | 13 | 12 | 61 | 50 | 46 | 32 | 61 | 89 |
| Total Liabilities | 127 | 117 | 113 | 128 | 144 | 143 | 203 | 210 | 220 | 240 | 313 | 458 |
| Fixed Assets | 9 | 42 | 33 | 33 | 32 | 32 | 30 | 65 | 64 | 62 | 64 | 67 |
| CWIP | 0 | 0 | 1 | 3 | 20 | 30 | 65 | 3 | 4 | 6 | 47 | 140 |
| Investments | 72 | 49 | 53 | 56 | 53 | 52 | 60 | 71 | 62 | 72 | 72 | 75 |
| Other Assets | 46 | 25 | 26 | 35 | 38 | 30 | 47 | 71 | 90 | 100 | 129 | 176 |
| Total Assets | 127 | 117 | 113 | 128 | 144 | 143 | 203 | 210 | 220 | 240 | 313 | 458 |
Cash Flow
| Mar 2015 | Mar 2016 | Mar 2017 | Mar 2018 | Mar 2019 | Mar 2020 | Mar 2021 | Mar 2022 | Mar 2023 | Mar 2024 | Mar 2025 | Mar 2026 | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Operating | -8 | 17 | 1 | 1 | 0 | 4 | 46 | 6 | 3 | -2 | 18 | 24 |
| Investing | -31 | -20 | -2 | -4 | -14 | -10 | -38 | -15 | 8 | -8 | -40 | -100 |
| Financing | 0 | 0 | 0 | 6 | 17 | 1 | 2 | 7 | -1 | 9 | 13 | 82 |
| Net Cash Flow | -39 | -2 | 0 | 2 | 3 | -5 | 10 | -2 | 10 | -1 | -9 | 6 |
| Free Cash Flow | -10 | -26 | 0 | -2 | -19 | -6 | 9 | -2 | -1 | -8 | -29 | -76 |
| CFO/OP | 430 | -442 | -202 | 25 | 60 | 1,598 | 877 | 79 | 39 | 23 | 82 | 92 |
Ratios
| Mar 2015 | Mar 2016 | Mar 2017 | Mar 2018 | Mar 2019 | Mar 2020 | Mar 2021 | Mar 2022 | Mar 2023 | Mar 2024 | Mar 2025 | Mar 2026 | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Debtor Days | 243 | 286 | 196 | 148 | 86 | 109 | 122 | 132 | 142 | 149 | 156 | 186 |
| Inventory Days | 124 | 110 | 84 | 39 | 36 | 70 | 35 | 28 | 10 | 18 | 53 | 33 |
| Days Payable | 124 | 154 | 184 | 108 | 33 | 89 | 525 | 239 | 200 | 118 | 189 | 230 |
| Cash Conversion Cycle | 243 | 241 | 96 | 79 | 89 | 89 | -367 | -79 | -48 | 50 | 20 | -11 |
| Working Capital Days | 197 | 234 | 115 | 93 | 37 | 22 | -223 | -40 | -4 | 30 | 56 | 49 |
| ROCE % | — | -10% | -9% | 5% | 6% | 1% | 3% | 6% | 10% | 13% | 16% | 13% |
Documents
1
Board Meeting Intimation for Considering And Approval Of The Audited Financial Results For The Quarter And Year Ended 31St March 2026
7 May - Board to meet on 15 May 2026 to approve audited standalone and consolidated FY26 results; trading window closed from 1 April 2026. 7 May - Board to meet on 15 May 2026 to approve audited standalone and consolidated FY26 results; trading window closed from 1 April 2026.
2
Compliances-Certificate under Reg. 74 (5) of SEBI (DP) Regulations, 2018
14 Apr - Submitting certificate under regulation 74(5) of SEBI (DP) Regulations received from MUFG Intime India Private Limited, RTA of the Company 14 Apr - Submitting certificate under regulation 74(5) of SEBI (DP) Regulations received from MUFG Intime India Private Limited, RTA of the Company
4
Board Meeting Outcome for Allotment Of Bonus Equity Shares
25 Mar - Board approved 1,74,80,782 bonus shares (1:1); record date 24 Mar 2026; paid-up capital doubled. 25 Mar - Board approved 1,74,80,782 bonus shares (1:1); record date 24 Mar 2026; paid-up capital doubled.
Frequently Asked Questions about Kilitch Drugs (India) Ltd
What does Kilitch Drugs (India) Ltd do?
Incorporated in 1978, Kilitch Drugs Ltd is engaged in the operation and management of Pharmaceutical Products[1]
Where is Kilitch Drugs (India) Ltd (KILITCH) listed?
Kilitch Drugs (India) Ltd is listed on the Indian stock exchanges. It is listed on NSE: KILITCH and BSE: 524500. You can view its live share price, financials, and ratios on Tapetide.
Which sector does Kilitch Drugs (India) Ltd belong to?
Kilitch Drugs (India) Ltd operates in the Healthcare sector within the Pharmaceuticals industry. Sector classification helps investors compare companies affected by similar economic conditions and regulatory changes.
What is the market capitalisation of Kilitch Drugs (India) Ltd?
Kilitch Drugs (India) Ltd has a market capitalisation of approximately ₹580.36 Cr. Based on this, it is classified as a Small Cap stock.
What is the PE ratio of Kilitch Drugs (India) Ltd?
The Price-to-Earnings (PE) ratio of Kilitch Drugs (India) Ltd is 19.91. The PE ratio compares a company's share price to its earnings per share and is commonly used to assess whether a stock is overvalued or undervalued relative to its peers.
What is the 52-week high and low of Kilitch Drugs (India) Ltd?
Over the past 52 weeks, Kilitch Drugs (India) Ltd has traded between a low of ₹117.25 and a high of ₹439. This range helps investors understand the stock's price volatility and recent trading levels.
What is the Return on Equity (ROE) of Kilitch Drugs (India) Ltd?
Kilitch Drugs (India) Ltd has a Return on Equity (ROE) of 10.66%. ROE measures how effectively a company uses shareholders' equity to generate profits. A higher ROE generally indicates better capital efficiency.
How can I research Kilitch Drugs (India) Ltd on Tapetide?
On Tapetide, you can view Kilitch Drugs (India) Ltd's live share price, quarterly results, profit & loss statements, balance sheet, cash flow, key ratios, shareholding pattern, technical indicators, analyst ratings, and forecasts — all on a single page without needing to sign up.
Company Information
Incorporated in 1978, Kilitch Drugs Ltd is engaged in the operation and management of Pharmaceutical Products[1]
Website kilitch.com
CEO Mr. Mukund Prataprai Mehta B.Com., LL.B.
Employees 187
Listed 2002-03-05
Face Value ₹ 10
Issued Size 1,74,80,782